Want to see PALI full AI Analyst Report?
Top Page
Palisade Bio
(NASDAQ:PALI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-29.58% Downside)
Action:Reiterated
Date:09/26/26
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and elevated cash burn) and bearish technicals (below key moving averages with negative MACD). The strongest support is the balance sheet’s low leverage and sizable equity base, while valuation is only modestly supportive because a negative P/E limits interpretability and no dividend yield is available.
Positive Factors
Low leverage and sizable equity base
Minimal debt and a sizable equity base provide financial flexibility for a development-stage biotech. This structure reduces leverage-related pressure and supports continued clinical execution, although the company remains dependent on its capital base while it has no meaningful product revenue.
Negative Factors
Pre-revenue business model
The absence of meaningful revenue leaves Palisade reliant on clinical development progress rather than recurring commercial cash inflows. Until a candidate is successfully developed and commercialized, operating performance will remain highly exposed to trial outcomes and funding requirements.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and sizable equity base
Minimal debt and a sizable equity base provide financial flexibility for a development-stage biotech. This structure reduces leverage-related pressure and supports continued clinical execution, although the company remains dependent on its capital base while it has no meaningful product revenue.
Read all positive factors
Palisade Bio (PALI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$277.09M
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)-0.07
Revenue GrowthN/A
EPS Growth91.31%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding174,270,550
10 Day Avg. Volume2,856,977
30 Day Avg. Volume3,118,077
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue633.24
Enterprise Value/Gross Profit633.24
Enterprise Value/Ebitda-9.53
Forecast
1Y Price Target
$10.17Price Target Upside377.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$428.57K
Palisade Bio Business Overview & Revenue Model
Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candid...
Palisade Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 500.00K | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| Gross Profit | 500.00K | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| EBITDA | -33.22M | -16.77M | -14.42M | -12.28M | -14.24M | -24.22M |
| Net Income | -31.94M | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
Balance Sheet | ||||||
| Total Assets | 127.31M | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M |
| Cash, Cash Equivalents and Short-Term Investments | 125.17M | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M |
| Total Debt | 0.00 | 71.00K | 169.00K | 369.00K | 404.00K | 199.00K |
| Total Liabilities | 5.57M | 4.96M | 3.39M | 2.74M | 3.28M | 5.15M |
| Stockholders Equity | 121.75M | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M |
Cash Flow | ||||||
| Free Cash Flow | -18.19M | -10.85M | -12.19M | -11.14M | -13.37M | -14.77M |
| Operating Cash Flow | -18.19M | -10.85M | -12.19M | -11.13M | -13.36M | -14.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.00K | -10.00K | -54.00K |
| Financing Cash Flow | 137.97M | 134.44M | 9.58M | 11.19M | 15.26M | 24.61M |
Palisade Bio Technical Analysis
Neutral
2.13
Price Trends
1.86
Negative
1.90
Negative
1.91
Negative
Market Momentum
-0.11
Negative
46.42
Neutral
77.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Neutral. The current price of 2.13 is above the 20-day moving average (MA) of 1.56, above the 50-day MA of 1.86, and above the 200-day MA of 1.91, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 77.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PALI.
Palisade Bio Risk Analysis
Palisade Bio disclosed 52 risk factors in its most recent earnings report. Palisade Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palisade Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $355.22M | -5.97 | -125.93% | ― | 986.14% | 45.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $240.36M | -1.43 | -215.23% | ― | 291.42% | 11.70% | |
45 Neutral | $277.09M | -2.99 | -33.47% | ― | ― | 91.31% | |
44 Neutral | $101.93M | -0.81 | -87.05% | ― | ― | -29.66% | |
42 Neutral | $198.28M | -2.46 | -136.45% | ― | ― | -1475.42% |
* Healthcare Sector Average
PALI
Palisade Bio
1.59
-0.26
-14.05%
CRBP
Corbus Pharmaceuticals
5.27
-10.98
-67.57%
ELDN
Eledon Pharmaceuticals
2.44
-0.27
-9.96%
OBIO
Orchestra BioMed Holdings
5.91
2.35
66.01%
PYXS
Pyxis Oncology
2.01
-1.22
-37.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.